Ambrosino Giovanni, Varotto Sergio, Strom Stephen C, Guariso Graziella, Franchin Elisa, Miotto Diego, Caenazzo Luciana, Basso Stefano, Carraro Paolo, Valente Maria Luisa, D'Amico Davide, Zancan Lucia, D'Antiga Lorenzo
Department of Surgery and Gastroenterological Science, University of Padova, Padova, Italy.
Cell Transplant. 2005;14(2-3):151-7. doi: 10.3727/000000005783983250.
Crigler-Najjar syndrome type 1 (CN1) is an inherited disorder characterized by the absence of hepatic uridine diphosphoglucuronate glucuronosyltransferase (UDPGT), the enzyme responsible for the conjugation and excretion of bilirubin. We performed allogenic hepatocyte transplantation (AHT) in a child with CN1, aiming to improve bilirubin glucuronidation in this condition. A 9-year-old boy with CN1 was prepared with plasmapheresis and immunosuppression with prednisolone and tacrolimus. When a graft was made available, 7.5 x 10(9) hepatocytes were isolated and infused into the portal vein percutaneously. After 2 weeks phenobarbitone was added to promote the enzymatic activity of UDPGT of the transplanted hepatocytes. Nocturnal phototherapy was continued throughout the studied period. Total bilirubin was considered a reliable marker of allogenic cell function. There was no significant variation of vital signs nor complications during the infusion. Mean +/- SD bilirubin level was 530 +/- 38 micromol/L before and 359 +/- 46 micromol/L after AHT (t-test, p < 0.001). However, the introduction of phenobarbitone was followed by a drop of tacrolimus level with increase of alanine aminotransferase (ALT) and increase of bilirubin. After standard treatment of cellular rejection bilirubin fell again but from then on it was maintained at a greater level. After discharge the patient experienced a further increase of bilirubin that returned to predischarge levels after readmission to the hospital. This was interpreted as poor compliance with phototherapy. Only partial correction of clinical jaundice and the poor tolerability to nocturnal phototherapy led the parents to refuse further hepatocyte infusions and request an orthotopic liver transplant. After 24 months the child is well, with good liver function on tacrolimus and prednisolone-based immunosuppression. Isolated AHT, though effective and safe, is not sufficient to correct CN1. Maintenance of adequate immunosuppression and family compliance are the main factors hampering the success of this procedure.
1型克里格勒-纳贾尔综合征(CN1)是一种遗传性疾病,其特征是肝脏中缺乏尿苷二磷酸葡萄糖醛酸葡萄糖醛酸基转移酶(UDPGT),该酶负责胆红素的结合和排泄。我们对一名患有CN1的儿童进行了同种异体肝细胞移植(AHT),旨在改善这种情况下的胆红素葡萄糖醛酸化。一名患有CN1的9岁男孩接受了血浆置换,并使用泼尼松龙和他克莫司进行免疫抑制。当有可用的移植物时,分离出7.5×10⁹个肝细胞,经皮注入门静脉。2周后添加苯巴比妥以促进移植肝细胞UDPGT的酶活性。在整个研究期间持续进行夜间光疗。总胆红素被认为是同种异体细胞功能的可靠标志物。输注过程中生命体征无明显变化,也无并发症。AHT前平均±标准差胆红素水平为530±38μmol/L,AHT后为359±46μmol/L(t检验,p<0.001)。然而,引入苯巴比妥后,他克莫司水平下降,丙氨酸转氨酶(ALT)升高,胆红素升高。在对细胞排斥进行标准治疗后,胆红素再次下降,但此后一直维持在较高水平。出院后患者胆红素进一步升高,再次入院后恢复到出院前水平。这被解释为对光疗的依从性差。仅临床黄疸部分得到纠正以及对夜间光疗耐受性差,导致患儿父母拒绝进一步的肝细胞输注,并要求进行原位肝移植。24个月后,患儿情况良好,在基于他克莫司和泼尼松龙的免疫抑制下肝功能良好。单独的AHT虽然有效且安全,但不足以纠正CN1。维持足够的免疫抑制和家庭依从性是阻碍该手术成功的主要因素。